Study summary

The objective of the study was to evaluate the efficacy, safety, tolerability and pharmacokinetics of mirabegron after multiple-dose administration in the pediatric population.

Additional Study Details

Phase
3
Product
mirabegron + solifenacin succinate
Product
Mirabegron
Type
Interventional
Masking
None (Open Label)
Enrollment number
91
Show Additional Study Details

Study documents

Scientific Results Summary
Available Language(s): English
Plain Language Summary
Available Language(s): English
Protocol
Available Language(s): English
Statistical Analysis Plan (SAP)
Available Language(s): English

Get more information

Would you like more information about clinical trial sites that are recruiting participants for Open-label Phase 3 Study with Mirabegron in Children From 3 to Less Than 18 Years of Age with Neurogenic Detrusor Overactivity? Contact us by filling out your information to the right and we’ll respond to you.

  • A caregiver
  • A healthcare provider
  • A parent
  • A patient
  • A patient advocate
  • Algeria
  • Argentina
  • Armenia
  • Australia
  • Austria
  • Belarus
  • Belgium
  • Bosnia And Herzegovina
  • Brazil
  • Bulgaria
  • Canada
  • Chile
  • China
  • Colombia
  • Croatia
  • Czech Republic
  • Denmark
  • Dominican Republic
  • Egypt
  • Estonia
  • Finland
  • Former Serbia and Montenegro
  • France
  • Georgia
  • Germany
  • Greece
  • Guatemala
  • Hong Kong
  • Hungary
  • Iceland
  • India
  • Indonesia
  • Ireland
  • Israel
  • Italy
  • Japan
  • Jordan
  • Kazakhstan
  • Latvia
  • Lebanon
  • Lithuania
  • Macedonia
  • Malaysia
  • Mexico
  • Montenegro
  • Morocco
  • Netherlands
  • New Zealand
  • Norway
  • Panama
  • Peru
  • Philippines
  • Poland
  • Portugal
  • Puerto Rico
  • Republic of Korea
  • Republic of Moldova
  • Romania
  • Russian Federation
  • Saudi Arabia
  • Serbia
  • Singapore
  • Slovakia
  • Slovenia
  • South Africa
  • Spain
  • Sweden
  • Switzerland
  • Taiwan, Province of China
  • Thailand
  • Turkey
  • Ukraine
  • United Kingdom
  • United States
  • Vietnam

By clicking ["Continue/Submit"], you agree that Astellas may contact you by email with information to help you connect with clinical trial sites. While we can connect you to clinical trial sites, we cannot answer questions about any investigational therapy through email. Your consent to receiving emails is not a requirement to participate in a clinical trial or study. For more information, including how to unsubscribe at any time, see our Privacy Notice & Cookies Policy.

    Locations

    Contact Us
    Contact Us
    Completed
    Site LV37101
    Riga, Latvia, LV-1004
    Completed
    Site DK45001
    Aarhus N, Denmark, DK-8200
    Withdrawn
    Site TR90005
    Ankara, Turkey, 06100
    Completed
    Site LT37002
    Kaunas, Lithuania, LT-50009
    Completed
    Site TR90006
    Bursa, Turkey
    Completed
    Site PL48001
    Gdansk, Poland, 80803
    Completed
    Site RO40002
    Bucuresti, Romania, 021495
    Completed
    Site KR82001
    Seoul, Republic of Korea, 03722
    Completed
    Site PH63001
    Quezon City, Philippines, 1100
    Withdrawn
    Site CO57002
    Cali, Valle del Cauca, Colombia, 760032
    Completed
    Site JO96201
    Irbid, Jordan, 22110
    Withdrawn
    Site BE32002
    Gent, Belgium, 9000
    Completed
    Site HR38503
    Zagreb, Croatia, 10000
    Completed
    Site NO47001
    Bergen, Norway, 5021
    Withdrawn
    Site TW88602
    Taipei, Taiwan, Province of China, 10002
    Completed
    Site SK42101
    Bratislava, Slovakia, 83301
    Completed
    Site PL48003
    Gdansk, Poland, 80-952
    Completed
    Site RS38102
    Nis, Serbia
    Withdrawn
    Site AU61001
    Park Ville VIC, Australia, 3052
    Completed
    Site MY60002
    Kuala Lumpur, Malaysia, 50586
    Completed
    Site BE32004
    Edegem, Belgium, B-2650
    Completed
    Site MX52002
    Mexico City, Mexico, 06700
    Completed
    Site PL48002
    Warszawa, Poland, 04-730
    Completed
    Site TW88601
    New Taipei City, Taiwan, Province of China, 23142
    Completed
    Site KR82002
    Seoul, Republic of Korea, 110744
    Completed
    Site RO40001
    Bucuresti, Romania, 22328
    Completed
    Site AU61002
    Randwick, NSW, Australia, 2031
    Withdrawn
    Site SK42102
    Martin, Slovakia, 036 59
    Completed
    Site HR38501
    Zagreb, Croatia, 10000
    Completed
    Site BE32001
    Gent, Belgium, 9000
    Completed
    Site DK45002
    Copenhagen, Denmark, 2100
    Completed
    Site IL97202
    Jerusalem, Israel, 91090
    Completed
    Site MY60001
    Georgetown, Malaysia, 10990
    Completed
    Site TR90008
    Mersin, Turkey, 33343
    Completed
    Site TR90002
    Ankara, Turkey, 06100
    Completed
    Site RS38101
    Novi Sad, Serbia, 21000
    Completed
    Site LT37001
    Vilnius, Lithuania, LT-08406
    Completed
    Site JO96202
    Amman, Jordan, 11183

    Frequently Asked Questions

    Are clinical trials only for people with advanced cancer?

    While some clinical trials may focus on more advanced cancers, many trials are open to patients at various stages of their cancer. Each study has rules about who can take part. For example, only patients in a certain age group or those who have a certain type of tumor may be able to join.

    Will I have to stop my current treatment to participate in a clinical trial?

    Sometimes researchers want participants to keep taking their current treatments during a clinical trial. Other times, you may need to stop your current treatments for a while. If the investigational treatment doesn't work, you can usually go back to your original treatment plan.

    Should I be worried about getting a placebo?

    In cancer clinical trials, a placebo is only used if there is no other treatment for that type of cancer. This helps compare an investigational treatment to the placebo. Placebos are rarely used in cancer trials because the best available treatment, called the “standard of care”, is usually given instead.

    Do I need a referral from my doctor to take part in a study?

    Your doctor may not know about all the opportunities for clinical trials that are available to you. Talk to your doctor or other medical provider about clinical trial information that you find. They can help you decide if a clinical trial is right for you. If you do not find any options on this website, we recommend you visit an online public registry website like clinicaltrials.gov to see a wide variety of available clinical trials.

    Explore More

    1

    What are clinical trials?

    2

    Why are Clinical Trials Important?

    3

    Why Participate in a Clinical Trial?